Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

461
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
461
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Folate receptor beta targeting of tumor-associated macrophages improves lymphoma cell responses to CD19 CAR T cells.

HemaSphere·2026
Same author

Spike conformational tuning rather than epitope erosion drives SARS-CoV-2 resistance to broadly neutralizing antibodies.

bioRxiv : the preprint server for biology·2026
Same author

A targeted circulating tumor DNA landscape of copy number aberrations in large B-cell lymphomas.

Leukemia·2026
Same author

DROP-CARs: Engineering Reversible, Drug-Controlled CAR T Cell Activity with a Clinically Approved Small Molecule.

Cancer research·2026
Same author

Spike-in probe-enhanced single-cell RNA-seq reveals post-infusion transcriptomic remodeling of "prime-and-kill" synNotch-CAR-T cells.

bioRxiv : the preprint server for biology·2026
Same author

Anti-spike IgG Avidity Enhances Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2: A Prospective Study of Primary Infections and Immunizations.

The Journal of infectious diseases·2026
Same journal

Targeting Cystine Addiction Suppresses Breast Cancer Lung Metastasis.

Cancer research·2026
Same journal

SEPTIN7 Enhances Tumorgenesis and Therapeutic Resistance in Hepatocellular Carcinoma by Promoting FGFR4 Stabilization and Recycling.

Cancer research·2026
Same journal

TLR9 Agonists Potentiate Adoptive T Cell Therapy in Cancer through a B Cell-CD2 Costimulatory Axis.

Cancer research·2026
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
查看所有相关文章

相关实验视频

Updated: May 24, 2025

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.5K

工程SH3衍生谢尔巴体功能作为针对性T细胞免疫疗法的模块化平台.

Rogelio A Hernández-López1, Tapio Kesti2, Anna R Mäkelä2

  • 1Department of Cellular and Molecular Pharmacology, Cell Design Institute, University of California San Francisco, San Francisco, California.

Cancer research
|March 3, 2025
PubMed
概括
此摘要是机器生成的。

工程化sherpabodies为仿真抗原受体 (CAR) T细胞疗法提供精确的瘤相关抗原识别. 这一突破提高了CAR T细胞对固体瘤的疗效,可能扩大治疗选择超出了血液癌症.

更多相关视频

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

62
Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.4K

相关实验视频

Last Updated: May 24, 2025

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.5K
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

62
Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.4K

科学领域:

  • 免疫学 免疫学 免疫学
  • 生物技术是生物技术.
  • 在瘤学瘤学.

背景情况:

  • 工程T细胞疗法在癌症治疗方面表现有前途,但由于抗原识别特异性和持久性有限,在固体瘤方面面临挑战.
  • 目前的仿真抗原受体 (CAR) T细胞策略在精确准固体瘤相关抗原 (TAA) 方面存在困难.

研究的目的:

  • 引入sherpabodies,新型抗体模拟蛋白,作为工程T细胞疗法中精确TAA识别的新平台.
  • 开发和评估sherpabody引导CARs (SbCARs) 以提高针对固体瘤的特异性,有效性和多功能性.

主要方法:

  • 来自人类SH3域支架的工程sherpabodies使用菌体显示器进行TAA识别.
  • 谢尔巴体被纳入第二代CAR结构 (SbCAR) 中,并进行了体外特异性和细胞毒性测试.
  • 多特异性和可诱导的SbCAR系统在异种移植小鼠模型中设计和评估.

主要成果:

  • 谢尔巴体表现出精确的TAA识别,没有对相关蛋白质的交叉反应.
  • 在实验室中,SbCARs对固体癌症TAA表现出强大的特异性和细胞毒性.
  • 在体内研究显示,SbCAR T细胞具有剂量依赖的抗瘤反应,可诱导系统增强了持久性和活性.

结论:

  • 谢尔巴体代表了一种多功能和小规模的蛋白质平台,用于下一代CAR T细胞疗法,特别是在固体瘤中.
  • SbCARs显示出克服CAR T细胞治疗固体癌症当前局限性的巨大潜力.
  • 这项技术可以扩大CAR T细胞疗法的成功范围,从血液性恶性瘤到固体瘤.